The only HALEU enrichment company in the Western world has a market value of just $4 billion—now sold at half price, a five-year call option on U.S. nuclear energy sovereignty.

**

📌 One Sentence Summary

An American company in the Western world that is the only commercial producer of HALEU (High-Assay Low-Enriched Uranium), holding $2B in cash, $3.8B in orders extending to 2040, and a DOE “favorite son” status—market cap only 3.8B. According to Greenwald’s reset cost method, rebuilding an equivalent-scale plant would cost 192837465657483.91T. The market is only willing to pay half.

$40 Current $100 | 12-month target $270 (+34%)| 5-year target $550-$1,200 (+172% to +494%)

👋 What happened to this company?

First, let me show you a set of contrasting numbers.

October 28, 2025: stock price $464.25, all-time high April 17, 2026: stock price $202.02—6 months crash of -56.5%

Meanwhile, the company’s fundamentals:

• January 5, 2026: DOE awarded a $LEU$ ten-year HALEU mission order
• Cash: $2.0B (about 49% of market cap)
• Order backlog: $3.8B, contracts extended to 2040
• Market position: the only commercial HALEU enrichment provider in the Western world, bar none

On one side, rigid fundamental improvement; on the other, a brutal stock price retracement.

That’s why I’m taking the time to write this—this isn’t a junk stock collapse, it’s a strategic asset swallowed by emotion.

Let me explain it plainly so you can judge for yourself.

🔬 Part One: What exactly is HALEU?

First, a term most investors are unfamiliar with.

HALEU = High-Assay Low-Enriched Uranium

Simply put: nuclear fuel is classified into four levels based on uranium-235 concentration—

→ Natural uranium (0.711%): mined ore, not directly usable as fuel → LEU (Low-Enriched Uranium, 3%-5%): the mainstream fuel used in over 440 nuclear reactors worldwide → HALEU (High-Assay Low-Enriched Uranium, 5%-20%): dedicated fuel for next-generation advanced reactors → HEU (Highly Enriched Uranium, >20%): used in nuclear weapons

Key point: Advanced reactors—those you’ve recently seen in the news as “Small Modular Reactors (SMRs)”—all require HALEU.

It’s not an upgrade of LEU; it’s a completely different fuel specification. Like your car running on 95 octane fuel—you can’t put 92 octane in.

Who needs HALEU? → Bill Gates’ TerraPower Natrium reactor (got the first non-light-water reactor construction permit in the US in March 2026) → Amazon-backed X-energy’s Xe-100 (signed data center PPA with AWS) → Sam Altman’s Oklo Aurora → Kairos Power’s KP-FHR (powering Google data centers) → Radiant, Westinghouse, Lightbridge…

These companies have dozens of reactors queued for design and construction. They need HALEU to operate.

Currently, only two entities worldwide can produce HALEU commercially:

→ Russia’s Rosatom via TENEX (veteran, 30 years of mature technology) → The US’s Centrus Energy (the only Western producer)

This is the first dramatic fact: the US has built many advanced nuclear reactors but has no domestic fuel supply.

🇷🇺 Part Two: Sanctions on Russia—an ongoing supply chain disruption

Before the Russia-Ukraine war in 2022, 24% of uranium enrichment services for the 94 US reactors came from Russia.

That’s not a small number. It’s a major artery of the supply chain.

After the war broke out, US Congress spent two years arguing, finally passing the “Prohibition of Russian Uranium Imports Act” (H.R. 1042) in May 2024:

→ Immediate import restrictions → Phased down to zero by end of 2027 → Complete embargo starting January 1, 2028 → Some provisions extend to 2040

Meaning: the 30-year US dependence on Russian nuclear fuel must be cut off within 3 years.

Then, the question: where does the fuel come from after the cut?

Answer A: Urenco (UK-Germany-Netherlands consortium)—has capacity, but “allied” label is politically sensitive for the US Department of Energy Answer B: Orano (French state-owned)—has applied for a new Tennessee plant, but not operational until 2029 Answer C: Centrus Energy—the only US-based, domestically manufactured, operated commercial enrichment provider

From a national security perspective, Centrus is the most politically correct choice—because it’s “America’s own.”

This is the second dramatic fact: a small company unexpectedly sitting at the crossroads of great power geopolitics.

🏭 Part Three: Why is this $4 billion small company so important?

Centrus is headquartered in Piketon, Ohio, a tiny town you can’t find on most maps.

But it has three nearly uncopyable barriers:

Barrier 1: NRC Category II HALEU production license The US Nuclear Regulatory Commission’s second-class special enrichment license—only one in the US. How long to get it? Over ten years of technical validation, hundreds of millions of dollars in pre-investment, and a full safety review process.

Barrier 2: AC100M centrifuges—US proprietary technology This is a legacy of US enrichment technology since the 1950s, iterated over 70 years. Supply chain covers 14 states, 13 manufacturers, completely independent of Urenco’s TC-21 patent system—meaning everything from engineers to screws is “Made in USA.”

Barrier 3: Deep integration with DOE

• Since 2019, exclusive HALEU operation contract
• June 2025, Phase 2 contract extension
• January 2026, $202 ELBM ten-year mission order
• NNSA (National Nuclear Security Administration) “single-source procurement” intent (exclusive military supply)

Total: $1.16B DOE contracts + potential NNSA military increments—this isn’t a consumer electronics company; it’s a strategic US government contractor.

And look at the market cap: $3.97B.

Compare:

→ TerraPower (pre-IPO) recent valuation $900M → Oklo (O-K-L-O) about $8B market cap, no power sales yet → NuScale (SMR) about $4B, first SMR project canceled → Centrus: actual revenue $448M, in production, $3.8B orders—market cap $3.97B

This is the third dramatic fact: a commercial-stage strategic contractor valued only as a concept stock that hasn’t yet produced.

💸 Part Four: Why did the stock fall from $900M to $202?

This is a question that must be answered straightforwardly. If not, it’s just bullish bias.

I break the -56% retracement into four parts:

Part 1: Frenzied revaluation (-25%) July 2024: $40, October 2025: $464—almost 12x in 16 months. The SMR narrative + sanctions + AI data center nuclear hype—overheated. A 25% drop is valuation digestion, normal.

Part 2: Q4 2025 EPS below expectations (-15%) February 11, 2026: Q4 earnings report—EPS below expectations by 44%. Reason: renegotiation of Phase 2 contract rates (undefinitized), gross margin temporarily unconfirmed, causing segment gross profit to drop from $17.6M to $6M. This is an accounting lag, not a business deterioration—but markets ignore that and sell off.

Part 3: $12B ATM dilution fears (-10%) November 2025: company launched new 192837465657483.91T ATM (at-the-market) share offering. ATM means issuing new shares at market price anytime—diluting existing shareholders. Full-year 2025, 22% dilution; if all $464 is issued, another 15-20% dilution. Shorts seize on this.

Part 4: UBS and Citi cut target prices consecutively (-6%) UBS from $1B to $195, Citi downgrades—institutions start to disagree.

Key judgment: In these four parts, the first three are “sentiment” and “accounting” issues, not fundamental deterioration. Orders are increasing, cash is rising, HALEU delivery is progressing, DOE contracts expanding.

This is the fourth dramatic fact: fundamentals are improving, stock price is retracing—that’s the classic “reversible crisis” definition.

💎 Part Five: Valuation—straight to the conclusion

Following my usual approach, I used 16 valuation methods for cross-validation. The detailed calculations are too technical, so I’ll just give the conclusion—

Three anchor prices:

→ Conservative anchor (Greenwald’s reset cost method): How much does it cost to build an equivalent plant from scratch? 2B. Centrus’s current EV is 3.8B. The market is saying “building costs > current valuation.”

→ Neutral anchor (DCF cash flow discount): Assuming HALEU reaches 6 MT/year by 2030, stable at $12,000/kg, WACC 9.2%, the company’s value is this number.

→ Aggressive anchor (Franchise Value monopoly premium): Adding a 40% 5-year monopoly premium for being the “only Western HALEU producer”—an optimistic scenario.

Weighted intrinsic value: $420. Current stock price: $202. Discount: 52%.

Time-based target prices:

→ 12 months: $235-$310 (midpoint $270, +34%) → 3 years: $380-$620 (midpoint $500, +148%) → 5 years: $550-$1,200 (midpoint $875, +333%)

Where does the upside come from?

1. Piketon expanding from 1 cascade to 16, 16x capacity
2. HALEU price hitting $15,000/kg, re-evaluating unit economics
3. SMR commercialization exploding after 2030
4. US government loan guarantees (LPO) + NNSA military orders

Downside risks?

1. $10 ATM fully executed, dilution pressure released
2. Piketon 16-cascade expansion fails (like USEC’s ACP in 2009)
3. Urenco Capenhurst HALEU production accelerates in 2031
4. US-Russia nuclear fuel trade exemption agreements

📊 Part Six: Positioning strategy (for followers)

Straightforward table, no fluff—

$1B Positioning Table

Max position: 5% (non-core, small-cap nuclear energy, high volatility)

❗ Six key signals to sell:

1. Piketon 16-cascade expansion delayed >18 months
2. $LEU$ ATM fully executed + refinancing > $180
3. DOE Phase III Option 2 not exercised in June 2027
4. Urenco Capenhurst HALEU production a year ahead
5. US-Russia nuclear fuel trade exemption agreement emerges
6. CEO Amir Vexler departs due to disagreements / SEC investigation

🎯 Part Seven: One sentence of investment philosophy

This isn’t a “bottom-fishing for 10x gains” target.

It’s a “5-year US nuclear sovereignty call option.”

Upside: If the US truly rebuilds its nuclear fuel supply chain and SMRs go commercial by 2030, Centrus becomes the key contractor in this hundred-billion-dollar national project—$800-$1,200 stock price is a baseline scenario, not an optimistic one.

Downside: If Piketon expansion fails, $210 ATM fully dilutes, or laser enrichment technology disrupts—$E19@ back to $E19@ isn’t surprising.

Odds: 3-6x upside / 40-50% downside.

This is alpha that requires conviction and discipline to capture. Lazy investors and short-term traders won’t hold.

⚠️ Four critical warning signals (disclosure)

To stay transparent, I list four negative signals that keep me awake:

1. Insiders continuously sell, none buy on open market. Former CFO Kevin Harrill sold all holdings at $150 in June 2025 (well below later peak). SVP Donelson, SVP Cutlip also sold out. No senior exec has bought a share publicly in the past 18 months.
2. No official public HALEU price. Industry estimates $10,000-$15,000/kg, but contracts with Centrus and TerraPower/X-energy are undisclosed. If future market expansion leads to lower prices, unit economics suffer.
3. Laser enrichment (SILEX/GLE) tech disruption risk from 2030+: Cameco’s joint venture Global Laser Enrichment secured $170 R&D + $98.9M state incentives, aiming for commercial operation by 2030. Success could cut costs 30-50% below Centrus—potential “Kodak moment” for Centrus.
4. Piketon 16-cascade expansion requires $2-3B capex. With only $2B cash on hand, execution delays or overruns would force refinancing—dilution or debt would depress valuation.

**

Just reading this already filters out a lot.

The market is never short of information; what’s lacking is willingness to repeatedly scrutinize logic.

If this content has given you some insight, please give a like 👍 or leave your thoughts 💬.

Every genuine feedback helps this account go further.

The platform’s recommendation system is essentially a form of “choice”: no interaction equals being deemed unnecessary.

If you agree with this data-and-logic-based approach, consider following for more research content.

If you don’t understand something, don’t rush—most of the time, understanding just takes time.

Risk warning: The views expressed here are personal opinions; no specific securities are recommended. Buy/sell at your own risk.

![]$120 https://img-cdn.gateio.im/webp-social/moments-1f1ac76a7d-31a79456b1-8b7abd-badf29.webp$140